Epigenomics and Affymetrix announced that Affymetrix has granted Epigenomics non-exclusive access to Affymetrix microarray technology to develop and market microarray-based in vitro diagnostic tests for oncology and other indications.

According to Epigenomics, this agreement complements its previously announced alliance with Qiagen. With the Affymetrix arrays and DNA analysis instrumentation, Epigenomics can now provide a complete platform for its pathology tests based on DNA methylation methods, according to the company.

Previous articleBrittle Prions Are More Infectious, Study Shows
Next articleFisher Biosciences Obtains Expanded PCR Rights from Applied Biosystems